If Australian companies shun their domestic market, who can blame multinationals?

Australian company Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner, Acadia Pharmaceuticals, reporting net sales of US$125 million in the second quarter of 2026.

The Federal Court of Australia has temporarily blocked Viatris from launching its tenofovir alafenamide and emtricitabine brands while Gilead's patent infringement proceedings are heard and resolved.

Moderna has begun vaccinating participants in a Phase 1 clinical trial of mRNA 1469, an investigational vaccine candidate designed to protect against Bundibugyo ebolavirus, or BDBV, a strain of Ebola virus disease for which no approved vaccine currently exists.

The role of community pharmacists is expected to expand further in the coming months, with 250 pharmacists nearing completion of advanced training through the University of Newcastle and UTS.

The PBS is an outlier when it comes to patient rights. It is not just the NDIS. Contrast the non-existence of a patient charter of rights for PBS decision-making with hospitals and aged care. Even private health insurers are subject to an ombudsman with investigatory powers. What makes this program uniquely resistant to patient agency and rights?

The Australian company had already worked with Lilly to prepare an advanced draft of the clinical study protocol before signing the significant agreement.

New Zealand's Pharmac says it is refreshing its patient advisory function to strengthen the way patient voices and lived experience inform its decisions.

The pricing outcomes negotiated in these agreements will likely have a far bigger impact on access outcomes than anything implemented as a result of the Health Technology Assessment Review.

Widespread reports of a potential merger between AstraZeneca and Bristol Myers Squibb that would bring together two of the pharmaceutical industry’s most influential oncology businesses.

Arrotex Pharmaceuticals, Australia's largest locally-owned pharmaceutical company, has announced the appointment of Dr Melinda Munns as Chief Medical Officer.

The classic story is a family sitting at home. Someone suggests driving to dinner. Nobody really wants to go, but each person thinks the others do, so everyone agrees. After an exhausting trip, they discover that everyone would have preferred to stay home. Sound familiar?

Mélanie Chamaux, General Manager of Servier Australia and New Zealand, described the listing as the result of a collective effort involving

Simon Dawson, General Manager, Kyowa Kirin Australia and Head of the APAC Cluster covering Australia, Korea and Taiwan, said the listing would provide an important option for eligible patients.

“As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia,” said Carlo Montagner, ST Chief Executive Officer.

Medicines Australia and the Generic and Biosimilar Medicines Association are understood to be maintaining their opposition to non-disclosure deeds as a condition of new agreement negotiations.

The events in the US this week surrounding a former public health leader raise some important questions in Australia about the accountability of 'independent experts'. Why we can't afford to muck up the AI opportunity as new evidence on its use emerges globally. Ongoing debate over access to medicines and the impact of global pricing.

Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients.

It will terrify some to imagine an even larger HTA industrial complex. Yet AI has the potential to fundamentally change its character and make it far more affordable and accessible for more organisations and people. It can open up an institutional framework that is about as accessible as an exclusive golf club.

A unique three‑way collaboration announced in Sydney seeks to build a practical blueprint for how Australia can confront a growing dementia crisis, with a particular focus on Alzheimer’s disease.